CGBIO (CEO Hyun-seung Yu), a specialist in bio regenerative medicine, announced on the 28th that it held a luncheon symposium at the recent ‘International Federation of Foot and Ankle Societies (IFFAS) 2024’ at COEX in Seoul, introducing its products as good treatment options in foot and ankle care based on clinical evidence.
IFFAS is a conference where orthopedic specialists from around the world gather for the advancement of scholarship, practice, research, exchange, and development in the field of foot and ankle studies. The world congress is held in rotation across five continents: North America, South America, Europe, Asia, and Oceania. This marks the first time it has been held in Asia, specifically in Korea. As the first offline conference since the COVID-19 pandemic, it attracted medical professionals and companies from around the world, including China, Japan, Southeast Asia, the United States, and Europe, providing an opportunity to exchange in-depth medical knowledge and the latest technologies in the orthopedic field.
The luncheon symposium, chaired by Hong-geun Jung, Director of the Foot and Ankle Center at Konkuk University Medical Center, featured presentations by Professor Kwang-hwan Park from Severance Hospital, Professor Young-hwan Park from Korea University Guro Hospital, and Professor Dong-woo Shim from Severance Hospital. They presented on the clinical applications of various CGBIO products including the bone substitute NOVOSIS, skin grafts CGDerm Matrix and CG Reallo Paste, injectable CG Reallo Inject, and the negative pressure wound therapy device CURAVAC.
First, Professor Kwang-hwan Park from Severance Hospital shared his clinical experience using these products in diabetic foot surgery under the theme ‘Use of CGDerm Matrix and CG Reallo Paste in Foot Wounds’. CGDerm Matrix is an acellular allogeneic dermis in sheet form that engrafts quickly and does not contract.
Professor Park introduced a clinical case of split-thickness skin grafting using CGDerm Matrix on an exposed tendon area after debridement of a large necrotic tissue due to diabetic foot. He stated, “The combination of inducing epithelialization with CURAVAC and simultaneous skin grafting using CGDerm Matrix as a dermal substitute tended to result in less contracture formation and shorter recovery time.”
He then introduced the use of CG Reallo Paste for irregular wounds such as soft tissue defects after foot amputation due to diabetic foot, and presented a protocol for foot and ankle wound management using ‘EasyFoam’ and the wound dressing ‘EasyDew MD Regen Cream’.
Professor Young-hwan Park from Korea University Guro Hospital presented clinical cases on ‘Foot and Ankle Surgery Using NOVOSIS Containing rhBMP-2’. He first introduced NOVOSIS and explained the function of hydroxyapatite as a carrier, emphasizing the safety and efficacy of NOVOSIS. He then shared that when NOVOSIS was applied to patients with a high risk of ankle joint non-union, fusion was confirmed and pain decreased after 12-16 weeks. Professor Park added, “NOVOSIS can be considered as a priority for patients with underlying diseases or smokers, who have a higher possibility of delayed bone union, due to its excellent osteoinductive properties.”
Professor Dong-woo Shim from Severance Hospital lectured on ‘Foot Surgery Using CG Reallo Inject’, discussing musculoskeletal regenerative therapy and foot and ankle cases. CG Reallo Inject, derived from human collagen, shows excellent biocompatibility.
In this lecture, Professor Shim shared clinical results showing musculoskeletal regeneration and reduced re-rupture rates, suggesting that the application range could be expanded. Professor Shim stated, “While CG Reallo Inject has mainly been used for regeneration of muscle and tendon ligament injuries, these clinical results confirm that it can also be used to treat foot inflammatory diseases such as chronic plantar fasciitis and Achilles tendinitis.”
Professor Hong-geun Jung, who chaired the luncheon symposium, not only elevated the symposium’s level with in-depth questions during the Q&A session about the application of foot wound and ankle disease treatment solutions, but also received high praise for providing immediately applicable clinical guidelines.
Hyun-seung Yu, CEO of CGBIO, said, “It was meaningful to widely publicize the extensive applicability of our products by sharing clinical cases applying them to foot and ankle treatments through this luncheon symposium. I’m particularly pleased that this opportunity allowed CGBIO’s unique regenerative medicine solutions for foot disease treatment to be recognized by medical professionals worldwide.” He added, “We will continue to lead the development of more innovative and effective regenerative medicine solutions for various disease treatments through ongoing research and development.”
▲ Professor Kwang-hwan Park from Severance Hospital giving a presentation at the IFFAS luncheon symposium
